Table 1 Baseline characteristics
Variable | NAVA (n = 39) | PSV (n = 38) |
|---|---|---|
Age, year (mean, SD) | 66.7 (13.9) | 67.1 (12.9) |
Males, n (%) | 26 (66.7) | 28 (73.7) |
BMI, kg/m2 (mean, SD) | 26.5 (4.7) | 26.4 (5.7) |
Duration of IMV pre-randomization, days (median, IQR) | 1.7 (1.1–3.1) | 1.7 (0.7–3.0) |
Duration of PSV pre-randomization, h (median, IQR) | 0.0 (0.0–4.0) | 0.0 (0.0–0.3) |
APACHE II (mean, SD) | 20.5 (6.0) | 20.1 (6.1) |
SOFA (median, IQR) | 8.0 (6.0–8.0) | 8.0 (5.5–10.0) |
PaO2/FiO2 ratio, mmHg (mean, SD) | 227.0 (82.0) | 242.0 (83.0) |
PEEP, cmH20 (mean, SD) | 8.9 (2.7) | 8.9 (2.8) |
RASS (median, IQR) | − 3.0 (− 4.0 to − 3.0) | − 4.0 (− 4.3 to − 3.0) |
Surgical admission, n (%) | 13 (33.3) | 17 (44.7) |
COPD, n (%) | 14 (35.9) | 13 (34.2) |
Heart failure, n (%) | 25 (64.1) | 26 (68.4) |
Acute respiratory distress syndrome, n (%) | 6 (15.4) | 8 (21.1) |
Primary ICU admission diagnosis, n (%) | ||
 Cardiovascular | 23 (59.0) | 20 (52.6) |
 Respiratory | 9 (23.1) | 13 (34.2) |
 Sepsis | 4 (10.3) | 3 (7.9) |
 Othera | 3 (7.7) | 2 (5.3) |
Comorbidities, n (%) | ||
 Chronic lung disease | 17 (43.6) | 16 (42.1) |
 Heart disease | 24 (61.5) | 28 (73.7) |
 Otherb | 25 (64.1) | 22 (57.9) |
Current smoker, n (%) | 6 (15.4) | 6 (15.8) |
Co-interventions at randomization, n (%) | ||
 Continuous inotrope or vasopressor infusion | 29 (74.1) | 31 (81.6) |
 Continuous sedation infusion | 36 (92.3) | 34 (89.5) |
 Continuous opioid infusion | 38 (97.4) | 37 (97.4) |
 Enteral or parenteral nutrition | 26 (66.7) | 26 (68.4) |
 Antibiotics | 35 (89.7) | 35 (92.1) |
 Invasive cardiac output monitoring | 19 (48.7) | 21 (55.3) |
 CRRT/dialysis | 13 (33.3) | 19 (50.0) |